Clinical trial
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis…
NCT05178862 · Scynexis, Inc., Industry · Terminated
Key facts
| NCT number | NCT05178862 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| Official title | A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO) |
| Acronym | MARIO |
| Lead sponsor | Scynexis, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Candidiasis, Invasive, Candidemia |
| Intervention type | Drug |
| Interventions | SCY-078, Fluconazole, Echinocandin |
| Enrollment | 68 |
| Start date | Aug 3, 2022 |
| Primary completion | Nov 7, 2025 |
| Completion | Dec 16, 2025 |
| First posted | Jan 5, 2022 |
| Last update posted | Dec 19, 2025 |
| Countries | Belgium, Bulgaria, Canada, China, France, Germany, Greece, Israel, Italy, South Africa, South Korea, Spain and 1 more |
At a glance
- 100–999 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: